摘要
目的分析恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎的效果。方法选择2018年3月至2019年3月我院收治的90例慢性乙型肝炎患者,采用随机数字表法将所有患者分成观察组与对照组,每组45例。对照组采用恩替卡韦治疗,观察组采用恩替卡韦联合聚乙二醇干扰素α-2a治疗,对比两组治疗效果。结果观察组的总有效率80.00%高于对照组的57.78%,差异具有统计学意义(P<0.05)。治疗6个月后观察组的HBV DNA转阴率、ALT复常率、HBeAg转阴率高于对照组,差异具有统计学意义(P<0.05)。治疗12个月后观察组的HBV DNA转阴率、ALT复常率、HBeAg转阴率高于对照组,差异具有统计学意义(P<0.05)。对比两组治疗6个月、12个月后的HBeAg血清转换率,无显著性(P>0.05)。结论采用恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎,疗效突出,安全可靠,值得推广应用。
Objective To analyze the effect of entecavir combined with polyethylene glycol interferonα-2a in the treatment of chronic hepatitis B.Methods Ninety patients with chronic hepatitis B from March 2018 to March 2019 were selected,and all patients were divided into observation group and control group with 45 cases.The control group was treated with entecavir and the observation group was treated with entecavir combined with polyethylene glycol interferonα-2a.Results The total effective rate of 80.00%was higher than the control group's 57.78%,and the difference was statistically significant(P<0.05).After 6 months of treatment,HBV DNA revulsion rate,ALT relapse rate and HBeAg revulsion rate were higher in the observation group than in the control group,the difference was statistically significant(P<0.05).The difference was statistically significant in the observation group after 12 months with HBV DNA revulsion,ALT revulsion and HBeAg revulsion compared with the control group(P<0.05).The conversion rates of HBeAg serum after 6 months and 12 months of treatment were not significantly compared between the two groups(P>0.05).Conclusion Enticavir combined with polyethylene glycol interferonα-2a is effective in the treatment of chronic hepatitis B.It is safe and reliable,and is worth promoting and applying.
作者
王莹
WANG Ying(Digestive Hepatology Division,Fuxin Infectious Diseases Hospital,Fuxin 123000,China)
出处
《中国医药指南》
2021年第33期119-120,共2页
Guide of China Medicine
